The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Early and protective microglial activation in Alzheimer’s disease: a prospective study using18F-DPA-714 PET imaging
Open accessAbstract
While emerging evidence suggests that neuroinflammation plays a crucial role in Alzheimer's disease, the impact of the microglia response in Alzheimer's disease remains a matter of debate. We aimed to study microglial activation in early Alzheimer's disease and its impact on clinical progression using a second-generation 18-kDa translocator protein positron emission tomography radiotracer together with amyloid imaging using Pittsburgh compound B positron emission tomography. We enrolled 96 subjects, 64 patients with Alzheimer's disease and 32 controls, from the IMABio3 study, who had both (11)C-Pittsburgh compound B and (18)F-DPA-714 positron emission tomography imaging. Patients with Alzheimer's disease were classified as prodromal Alzheimer's disease (n = 38) and Alzheimer's disease dementia (n = 26). Translocator protein-binding was measured using a simple ratio method with cerebellar grey matter as reference tissue, taking into account regional atrophy. Images were analysed at the regional (volume of interest) and at the voxel level. Translocator protein genotyping allowed the classification of all subjects in high, mixed and low affinity binders. Thirty high+mixed affinity binders patients with Alzheimer's disease were dichotomized into slow decliners (n = 10) or fast decliners (n = 20) after 2 years of follow-up. All patients with Alzheimer's disease had an amyloid positive Pittsburgh compound B positron emission tomography. Among controls, eight had positive amyloid scans (n = 6 high+mixed affinity binders), defined as amyloidosis controls, and were analysed separately. By both volumes of interest and voxel-wise comparison, 18-kDa translocator protein-binding was higher in high affinity binders, mixed affinity binders and high+mixed affinity binders Alzheimer's disease groups compared to controls, especially at the prodromal stage, involving the temporo-parietal cortex. Translocator protein-binding was positively correlated with Mini-Mental State Examination scores and grey matter volume, as well as with Pittsburgh compound B binding. Amyloidosis controls displayed higher translocator protein-binding than controls, especially in the frontal cortex. We found higher translocator protein-binding in slow decliners than fast decliners, with no difference in Pittsburgh compound B binding. Microglial activation appears at the prodromal and possibly at the preclinical stage of Alzheimer's disease, and seems to play a protective role in the clinical progression of the disease at these early stages. The extent of microglial activation appears to differ between patients, and could explain the overlap in translocator protein binding values between patients with Alzheimer's disease and amyloidosis controls.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aβ itself acts as a proinflammatory agent, activating many inflammatory components.”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the early stages of AD, initial microglial activation may serve a protective role (anti-neuroinflammatory), whereby it tries to clear the amyloid and release nerve growth factors. However, when Aβ or other toxic products over-accumulate, proinflammatory phenotypes are activated, which damage the neurons [26].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the brains of patients with AD exhibited evidence of sustained inflammation.”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“[18F]DPA-714 was extensively studied in preclinical and clinical models [58–61], as a biomarker of neuroinflammation in various human CNS disorders [58].”
From Neuron secrete exosomes containing miR-9-5p to promote polarization of M1 microglia in depression (2022) · cites this paper as [58]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, early neuroinflammation has been shown to be an adaptive mechanism by microglia that protects against AD pathology by reducing the levels of Aβ and tau.118–120”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [120]
In the citing paper
“In vivo imaging shows that microglia activation precedes the onset of AD (100) and is paralleled by increased levels of inflammatory markers in the cerebrospinal fluid (101)”
From Microglia in Alzheimer's disease (2017) · cites this paper as [100]
In the citing paper
“in MCI, microglial activation was positively correlated with cognition and gray matter volume, suggesting that microglial activation plays a protective role in the early phase of clinically apparent disease (100).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [100]
In the citing paper
“Of relevance, PET studies have indicated increased microglia activation in the precuneus and parietal cortex in AD.47,48”
From CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease (2018) · cites this paper as [48]
In the citing paper
“Another study that divided AD subjects into fast decliners and slow decliners measured a higher TSPO signal in the brains of slow decliners, consistent with a protective role for microglial activation even in stages of AD when dementia is evident (Hamelin et al., 2016).”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Hamelin et al., 2016
In the citing paper
“This is consistent with the finding that early microglial activation in response to amyloid plaques, as assessed by in vivo microglial imaging studies, is correlated with increased grey matter volume and reduced rate of cognitive decline46,47.”
In the citing paper
“Methods to image microglia exist and are being used to test the effect of treatments on microglia205–210.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [209]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Self-citationIn-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054
Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
Microglia: Scapegoat, saboteur, or something else?
Aguzzi, A., Barres, B. A., & Bennett, M. L. (2013) · Science · doi:10.1126/science.1227901 · Cited by 836
The peripheral benzodiazepine binding site in the brain in multiple sclerosis
Banati, R. B., Newcombe, J., Gunn, R. N., Cagnin, A., Turkheimer, F., Heppner, F., Price, G., Wegner, F., Giovannoni, G., Miller, D. H., et al. (2000) · Brain · doi:10.1093/brain/123.11.2321 · Cited by 661
Conversion of amyloid positive and negative MCI to AD over 3 years
Okello, A., Koivunen, J., Edison, P., Archer, H. A., Turkheimer, F., Någren, K., Bullock, R. M., Walker, Z., Kennedy, A. M., Fox, N. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b23564 · Cited by 537
Lopresti, B. J., Klunk, W. E., Mathis, C. A., Hoge, J. A., Ziolko, S. K., Lu, X., MELTZER, C. C., Schimmel, K., Tsopelas, N. D., DeKosky, S. T., et al. (2005) · PubMed · Cited by 536
Edison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.001 · Cited by 513
Amnestic syndrome of the medial temporal type identifies prodromal AD
Sarazin, M., Berr, C., de Rotrou, J., Fabrigoule, C., Pasquier, F., Legrain, S., Michel, B. F., Puel, M., Volteau, M., Touchon, J., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000279336.36610.f7 · Cited by 487
Self-citationEarly-Versus Late-Onset Alzheimer's Disease: More than Age Alone
Koedam, E. L. G. E., Lauffer, V., van der Vlies, A. E., van der Flier, W. M., Scheltens, P., & Pijnenburg, Y. A. L. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1337 · Cited by 452
Il10 Deficiency Rebalances Innate Immunity to Mitigate Alzheimer-Like Pathology
Guillot-Sestier, M.-V., Doty, K. R., Gate, D., Rodriguez, J., Leung, B. P., Rezai-Zadeh, K., & Town, T. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.068 · Cited by 363
Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands
Owen, D. R., Gunn, R. N., Rabiner, E. A., Bennacef, I., Fujita, M., Kreisl, W. C., Innis, R. B., Pike, V. W., Reynolds, R., Matthews, P. M., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.079459 · Cited by 361
Chakrabarty, P., Li, A., Ceballos-Diaz, C., Eddy, J. A., Funk, C. C., Moore, B., DiNunno, N., Rosario, A. M., Cruz, P. E., Verbeeck, C., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.11.020 · Cited by 354
In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease
Kreisl, W. C., Lyoo, C. H., McGwier, M., Snow, J., Jenko, K. J., Kimura, N., Corona, W., Morse, C. L., Zoghbi, S. S., Pike, V. W., et al. (2013) · Brain · doi:10.1093/brain/awt145 · Cited by 350
de Jong, H. W. A. M., van Velden, F. H. P., Kloet, R. W., Buijs, F. L., Boellaard, R., & Lammertsma, A. A. (2007) · Physics in Medicine and Biology · doi:10.1088/0031-9155/52/5/019 · Cited by 347
Microglia actions in Alzheimer's disease
Prokop, S., Miller, K. R., & Heppner, F. L. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1182-x · Cited by 291
Lyoo, C. H., Ikawa, M., Liow, J., Zoghbi, S. S., Morse, C. L., Pike, V. W., Fujita, M., Innis, R. B., & Kreisl, W. C. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.146027 · Cited by 245
Shechter, R., & Schwartz, M. (2012) · The Journal of Pathology · doi:10.1002/path.4106 · Cited by 237
Chauveau, F., Camp, N. V., Dollé, F., Kühnast, B., Hinnen, F., Damont, A., Boutin, H., James, M. L., Kassiou, M., & Tavitian, B. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058669 · Cited by 236
Impact of Image-Space Resolution Modeling for Studies with the High-Resolution Research Tomograph
Sureau, F. C., Reader, A. J., Comtat, C., Leroy, C., Ribeiro, M. J., Buvat, I., & Trébossen, R. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045351 · Cited by 232
Self-citationYasuno, F., Ota, M., Kosaka, J., Ito, H., Higuchi, M., DORONBEKOV, T. K., Nozaki, S., Fujimura, Y., Koeda, M., Asada, T., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.021 · Cited by 229
Fan, Z., Aman, Y., Ahmed, I., Chetelat, G., Landeau, B., Ray Chaudhuri, K., Brooks, D. J., & Edison, P. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.016 · Cited by 212
Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study
Schuitemaker, A., Kropholler, M. A., Boellaard, R., van der Flier, W. M., Kloet, R. W., van der Doef, T. F., Knol, D. L., Windhorst, A. D., Luurtsema, G., Barkhof, F., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.021 · Cited by 175
Wiley, C. A., Lopresti, B. J., Venneti, S., Price, J. C., Klunk, W. E., DeKosky, S. T., & Mathis, C. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.511 · Cited by 160
Versijpt, J. J., Dumont, F., van Laere, K. J., Decoo, D., Santens, P., Audenaert, K., Achten, E., Slegers, G., Dierckx, R., & Korf, J. (2003) · European Neurology · doi:10.1159/000070857 · Cited by 152
Time-dependent reduction in Aβ levels after intracranial LPS administration in APP transgenic mice
Herber, D. L., Roth, L. M., Wilson, D. H., Wilson, N., Mason, J. E., Morgan, D., & Gordon, M. N. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.07.007 · Cited by 151
Yasuno, F., Kosaka, J., Ota, M., Higuchi, M., Ito, H., Fujimura, Y., Nozaki, S., Takahashi, S., Mizukami, K., Asada, T., et al. (2012) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2011.08.013 · Cited by 148
Herber, D. L., Mercer, M., Roth, L. M., Symmonds, K., Maloney, J. L., Wilson, N., Freeman, M. J., Morgan, D., & Gordon, M. N. (2007) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-007-9069-z · Cited by 143
Similar amyloid-β burden in posterior cortical atrophy and Alzheimer's disease
de Souza, L. C., Corlier, F. W., Habert, M., Uspenskaya, O., Maroy, R., Lamari, F., Marie Chupin, A., Lehéricy, S., Olivier Colliot, A., Hahn‐Barma, V., et al. (2011) · Brain · doi:10.1093/brain/awr130 · Cited by 134
Self-citationRamanan, V. K., Risacher, S. L., Nho, K., Kim, S., Shen, L., McDonald, B. C., Yoder, K. K., Hutchins, G. D., West, J. D., Tallman, E. F., et al. (2015) · Brain · doi:10.1093/brain/awv231 · Cited by 133
Golla, S. S. V., Boellaard, R., Oikonen, V., Hoffmann, A., van Berckel, B. N. M., Windhorst, A. D., Virta, J. R., Haaparanta‐Solin, M., Luoto, P., Savisto, N., et al. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.261 · Cited by 132
Most rapid cognitive decline in APOE ε4 negative Alzheimer's disease with early onset
van der Vlies, A. E., Koedam, E., Pijnenburg, Y. A. L., Twisk, J. W. R., Scheltens, P., & van der Flier, W. M. (2009) · Psychological Medicine · doi:10.1017/s0033291709005492 · Cited by 107
Lockhart, A., Davis, B., Matthews, J. C., Rahmoune, H., Hong, G., Gee, A. D., Earnshaw, D. L., & Brown, J. (2003) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(02)00410-9 · Cited by 105
Varrone, A., Oikonen, V., Forsberg, A., Joutsa, J., Takano, A., Solin, O. H., Haaparanta‐Solin, M., Nag, S., Nakao, R., Al‐Tawil, N. G., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2955-8 · Cited by 83
Lavisse, S., García-Lorenzo, D., Peyronneau, M., Bodini, B., Thiriez, C., Kühnast, B., Comtat, C., Rémy, P., Stankoff, B., & Bottlaender, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.156083 · Cited by 75
Self-citationAnti-inflammatory Signaling in Microglia Exacerbates Alzheimer’s Disease-Related Pathology
Michaud, J.-P., & Rivest, S. (2015) · Neuron · doi:10.1016/j.neuron.2015.01.021 · Cited by 69
Belloli, S., Moresco, R. M., Matarrese, M., Biella, G. E. M., Sanvito, F., Simonelli, P., Turolla, E. A., Olivieri, S., Cappelli, A., Vomero, S., et al. (2003) · Neurochemistry International · doi:10.1016/j.neuint.2003.08.006 · Cited by 55
Wood, P. L. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-297-5_15 · Cited by 10
Flagged first, then by citations
1 of the 41 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Lane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935
Microglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Metadata
- Authors
- Hamelin, L., Lagarde, J., Dorothée, G., Leroy, C., Labit, M., Comley, R. A., de Souza, L. C., Corne, H., Dauphinot, L., Bertoux, M., Dubois, B., Gervais, P., Colliot, O., Potier, M. C., Bottlaender, M., Sarazin, M., & the Clinical IMABio3 team
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Centre d'Acquisition et de Traitement des Images (FR)
- F. Hoffmann-La Roche AG (CH)
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-03-15
- Volume
- 139
- Issue
- 4
- Pages
- 1252-1264
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2298656843
- Cited by
- 519
- References
- 41
- Citations by year
- 2026: 38 · 2025: 48 · 2024: 71 · 2023: 59 · 2022: 47 · 2021: 47 · 2020: 51 · 2019: 51 · 2018: 57 · 2017: 39 · 2016: 10
- FWCI
- 28.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Funders
- European Commission (2007–2013, FP7 2007-2013, FP7/2007, 278850)
- Université Paris Descartes
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, microglial activation, translocator protein (TSPO), [18F]DPA-714, neuroinflammation, prodromal Alzheimer's disease, amyloid imaging, Pittsburgh compound B, clinical progression, amyloidosis, gray matter volume, temporoparietal cortex, frontal cortex, cognitive decline
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Fluorine Radioisotopes, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Pyrazoles, Pyrimidines, Cohort Studies, Microglia, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
